July 26 (Reuters) - Intellipharmaceutics International Inc IPCI.TO -
* FDA panel votes 22-1 against approving Intelli's opioid painkiller
* FDA panel votes 4-19 to support claim that Intelli's opioid painkiller has properties that can be expected to deter abuse by IV route of administration
* FDA panel votes unanimously against claim that there is sufficient data on intelli drug to include abuse-deterrent properties on label for IV route of administration Further company coverage: IPCI.TO